RAINBOW

Rainbow Children's Medicare Limited announced the availability of the audio recording of its conference call with investors/analysts held on May 25, 2026, at 10:00 AM (IST). The call discussed the financial and operational performance for the quarter and financial year ended March 31, 2026. The recording is accessible on the company's website.

The Board of Directors of Rainbow Children's Medicare Limited, in a meeting on May 23, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of ₹3.5/- per Equity Share for FY 2025-26, subject to shareholder approval. Additionally, the Board approved the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, and Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors for five-year terms. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY 2026-27.

The Board of Directors of Rainbow Children's Medicare Limited, in its meeting on May 23, 2026, approved the audited financial results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per equity share for FY26, subject to shareholder approval at the 28th AGM on July 29, 2026, with July 21, 2026, as the record date. Additionally, the re-appointments of the Chairman & MD, Whole Time Director, two Independent Directors, and Cost Auditors were approved.

Rainbow Children's Medicare Limited's Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per Equity Share for FY 2025-26. Additionally, the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director, Dr. Dinesh Kumar Chirla as Whole Time Director, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors, and M/s. Lavanya & Associates LLP as Cost Auditors were approved, subject to shareholder consent.

Rainbow Children's Medicare Limited's Board of Directors, in its meeting on May 23, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per equity share for FY26, subject to AGM approval. Additionally, the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, and two Independent Directors (Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati) for five-year terms was approved. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY26-27.

The Board of Directors of Rainbow Children's Medicare Limited, in a meeting on May 23, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A final dividend of ₹3.50 per equity share for FY 2025-26 was recommended, subject to shareholder approval at the 28th Annual General Meeting on July 29, 2026. The Board also approved the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors, and M/s. Lavanya & Associates LLP as Cost Auditors for their respective terms.

On May 23, 2026, Rainbow Children's Medicare Limited's Nomination and Remuneration Committee granted 2,67,550 Stock Options under its ESOP Scheme 2025 to eligible employees. These options are exercisable into an equal number of equity shares, with an exercise price discounted by up to 20% from the previous day's NSE closing price. The options vest over a minimum of 1 year and are exercisable within two years from vesting.

Consolidated Revenue ₹459.9Cr vs ₹370.1Cr (▲24.3% YoY), EBITDA ₹144.7Cr vs ₹114.7Cr (▲26.1% YoY), PAT ₹78.2Cr vs ₹56.6Cr (▲38.3% YoY). EBITDA Margin 31.5% vs 31.0% (▲47bps).

Standalone Revenue ₹4,080.64 Mn vs ₹3,539.95 Mn (▲15.28% YoY), EBITDA ₹1,273.97 Mn vs ₹1,108.14 Mn (▲14.96% YoY), PAT ₹593.05 Mn vs ₹545.40 Mn (▲8.74% YoY). EBITDA Margin 31.22% vs 31.30% (▼8bps). The Board also recommended a final dividend of ₹3.5/- per Equity Share for FY26.

The Board of Directors of Rainbow Children's Medicare Limited approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. A final dividend of ₹3.5/- per equity share was recommended for FY 2025-26. The Board also approved the re-appointment of Dr. Ramesh Kancharla as CMD, Dr. Dinesh Kumar Chirla as WTD, and Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors for five-year terms. The 28th Annual General Meeting is scheduled for July 29, 2026.

Consolidated Revenue ₹459.90 Cr vs ₹370.11 Cr (▲24.3% YoY), EBITDA ₹143.16 Cr vs ₹114.73 Cr (▲24.8% YoY), PAT ₹78.22 Cr vs ₹56.55 Cr (▲38.3% YoY). EBITDA Margin 31.13% vs 30.99% (▲14bps). The Board also recommended a final dividend of ₹3.50 per equity share for FY 2025-26, and approved the re-appointment of key managerial personnel and independent directors.

Rainbow Children's Medicare Limited announced an Earnings Conference Call for Investors/Analysts on May 25, 2026, at 10:00 AM (IST). The call will discuss the financial and operating performance for the quarter and financial year ended March 31, 2026.

Rainbow Children's Medicare Limited announced that its appeal against a GST demand notice (under Section 74(5) of CGST Act, 2017) has been disallowed, and the original demand upheld by the Principal Commissioner of Customs and Central Tax (Appeals-1) on May 7, 2026. The company states there is no material impact on its financial position or operations at this stage and no payment has been made yet. The company is in the process of preferring a further appeal.

Rainbow Children's Medicare Limited announced the commencement of a new 60-bed spoke hospital in HRBR Layout and an IVF centre in Mahadevapura, Bengaluru, operational from May 4, 2026. The expansion, funded by internal accruals with a total investment of approximately ₹52 crore, increases the company's total bed capacity to ~2,435. This move strengthens its presence in high-growth micro-markets and enhances access to integrated pediatric, obstetric, and fertility services.